This study is being done to evaluate the safety, tolerability and effectiveness of Oral
CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small
lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant
to two or more lines of established therapy or for whom no other treatment options are
available.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03893682.
Locations matching your search criteria
United States
Maryland
Baltimore
University of Maryland/Greenebaum Cancer CenterStatus: Active
Contact: Janaiya Samuels
Phone: 410-328-8199
This is a multicenter, open-label, Phase Ia/b dose escalation study of safety,
pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to
determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or
Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase at
the MTD or recommended oral dose.
Lead OrganizationAptose Biosciences
